Although NDNB-25 and NDNB-21 have not yet been evaluated clinically, earlier Hsp90β-selective analogs, such as NDNB1182, demonstrated in vivo efficacy and favorable safety profiles when combined with immune checkpoint blockade in murine tumor models [52]. Here, HSP90AB1 is linked to neoplasm.